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Abstract
Background and Objective: Proteinuria assessment is key in investigating chronic kidney disease (CKD) but uncertainty
exists regarding optimal methods. Albuminuria, reflecting glomerular damage, is usually measured, but non-albumin
proteinuria (NAP), reflecting tubular damage, may be important. This study investigated the prevalence and associations of
albuminuria and NAP, and the optimum number of urine specimens required.
Methods: 1,741 patients with CKD stage 3, recruited from primary care, underwent medical history, clinical assessment,
blood sampling, and submitted three early morning urine samples for albumin to creatinine ratio (uACR) and protein to
creatinine ratios (uPCR). Albuminuria was defined as uACR $3 mg/mmol in at least two of three samples. Isolated NAP was
defined as uPCR$17 mg/mmol in two of three samples and uACR,3 mg/mmol in all three. Prevalence and associations of
albuminuria and NAP, degree of agreement between single uACR and average of three uACRs, and urine albumin to protein
ratio (uAPR=uACR/uPCR) were identified.
Results: Albuminuria prevalence was 16% and NAP 6%. Using a ,1 mg/mmol threshold for uACR reduced NAP prevalence
to 3.6%. Independent associations of albuminuria were: males (OR 3.06 (95% CI, 2.23–4.19)), diabetes (OR 2.14 (1.53–3.00)),
lower estimated glomerular filtration rate ((OR 2.06 (1.48–2.85) 30–44 vs 45–59), and high sensitivity CRP ((OR 1.70 (1.25–
2.32)). NAP was independently associated with females (OR 6.79 (3.48–13.26)), age (OR 1.62 (1.02–2.56) 80 s vs 70–79) and
high sensitivity CRP ((OR 1.74 (1.14–2.66)). Of those with uPCR$17 mg/mmol, 62% had uAPR,0.4. Sensitivity of single uACR
was 95%, specificity 98%, PPV 90%. Bland Altman plot one vs average of three uACRs showed: mean difference 0.0064 mg/mmol
(SD 4.69, limits of agreement 29.19 to +9.20, absolute mean difference 0.837).
Conclusions: In CKD stage 3, albuminuria has associations distinct from those of isolated NAP (except for inflammatory
markers). Single uACR categorised albuminuria but average of three performed better for quantification.
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Introduction
The assessment of proteinuria is a key element of the
investigation of kidney disease but some uncertainty exists
regarding the optimal methods to apply. Specific unresolved issues
include whether to measure total urinary protein and/or
albuminuria and the optimum number of urine specimens
required. People with chronic kidney disease (CKD) are at risk
of mortality, cardiovascular disease (CVD) and less commonly
progression to end stage renal disease (ESRD).[1,2] Proteinuria,
most often assessed as albuminuria, is a strong independent
predictor of renal, cardiovascular, and mortality risk. [1,3] An
increasing level of urinary albumin to creatinine ratio (uACR) is
independently associated with higher cardiovascular mortality risk
and CKD progression. This association exists in both men and
women, increases with age, and occurs in people with and without
diabetes.[4–10] A single uACR measure has been used to derive
risk in most cohort studies.[6–9]
Several CKD management guidelines, including those from the
UK National Institute for Health and Clinical Excellence (NICE),
the Kidney Disease Improving Global Outcomes (KDIGO) and
the Kidney Disease Outcomes Quality Initiative (K/DOQI),
recommend identification and quantification of proteinuria using
uACR in preference to protein to creatinine ratio (uPCR).[11–13]
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In addition, some guidelines recommend repeating uACR
measurements for initial identification of albuminuria to avoid
over diagnosis due to transient albuminuria changes. [11,14] It has
been argued that uPCR is a more sensitive screening test for
proteinuria; though uPCR and uACR perform similarly well in
predicting adverse outcomes. [15,16] Conversely, it could be
argued that assessment of both albuminuria and non-albumin
proteinuria (NAP) may provide valuable diagnostic and prognostic
information. Albuminuria typically reflects glomerular disease,
whereas NAP (including a2- and b2-microglobulins) is associated
with tubulointerstitial pathology, and a low urinary albumin to
total urinary protein ratio (uAPR) demonstrates strong correlation
with tubulointerstitial disease on renal biopsy. [16–18] Some
patients have a mixed proteinuria picture reflecting both
glomerular and tubular dysfunction, particularly as total protein
increases.[17] Little is known about the relative distributions of
albuminuria and NAP in people with CKD, or the demographic
and clinical associations of NAP or its prognostic significance.
This study aimed to investigate proteinuria assessment in a
population of people with CKD stage 3 in a primary care setting in
the UK, by determining the prevalence and associations of
albuminuria and NAP, and assessing degree of agreement between
a single uACR measure and two of three measures to identify
albuminuria.
Materials and Methods
The study was approved by Nottingham Research Ethics
Committee 1. All participants provided written informed consent.
The study was included on the National Institute for Health
Research (NIHR) Clinical Research Portfolio (NIHR Study ID:
6632) and was independently audited by QED Clinical Services in
November 2009. Participants were recruited for the Renal Risk in
Derby (RRID) study, a prospective cohort of people with CKD
stage 3 in a primary care setting. The methods for the RRID study
have been published in detail elsewhere. [19] In summary, eligible
participants were 18 years or over, met the Kidney Disease
Outcomes Quality Initiative criteria for CKD stage 3 (estimated
GFR (eGFR) between 30 to 59 ml/min per 1.73 m2 on two or
more occasions at least 3 months apart prior to recruitment), were
able to give informed consent, and were able to attend their
general practitioner (GP) surgery for assessments. People who had
previously had a solid organ transplant or who were terminally ill
(expected survival ,1 years) were excluded. The RRID study is
conducted by a single nephrology department, but participants
were recruited directly from 32 GP surgeries. Eligible patients
were invited to participate via a letter sent by their GP and
telephoned the coordinating centre to schedule a study visit. Study
visits were conducted at participating GP surgeries by the
researchers.
First study visits were conducted from August 2008 to March
2010. Screening and baseline visits were combined due to the large
proportion of elderly participants and the logistical challenges
associated with conducting study visits in multiple primary care
centres. Participants were sent a medical and dietary questionnaire
and three urine specimen bottles, and were asked not to eat cooked
meat for at least 12 hours before the assessment. Urine was
collected as three early morning samples on consecutive days
before the study visit and was stored in a refrigerator. Specimens
were submitted for analysis on the study visit day. Socioeconomic
status was defined by the Indices of Multiple Deprivation score
(IMD, a social deprivation score comprising a seven domain
composite measure that demonstrates a strong relationship to
health) and self-reported education status; an important indicator
of socioeconomic status in elderly populations. [20,21] Education
status was grouped into three for analysis (group one: no formal
qualifications, group two: General certificate of Secondary
Education (GCSE) or equivalent, Advanced level (A level), or
National Vocational Qualification (NVQ) 1–3, group three: first or
higher degree, NVQ 4–5). Self-reported ethnicity information was
collected. Due to small numbers of non-white participants, it was
categorized into ‘White’ and ‘Other’ for the purposes of analysis.
At the assessment, information on questionnaires was checked,
anthropomorphic measurements taken, and dipstick urinalysis
performed. If this suggested a urinary tract infection, a specimen
was submitted for microscopy and culture. Confirmed UTIs were
treated with antibiotics and urine biochemistry was repeated after
treatment. Blood specimens were taken and submitted for
biochemical analysis (including serum creatinine, blood lipids
and high sensitivity C–reactive protein (hsCRP, Roche Diagnos-
tics, Newhaven, UK)). Creatinine was measured by a single
autoanalyser using the Jaffe method and the assay was standard-
ised against an isotope dilution mass spectrometry (IDMS)
method. eGFR was calculated using the modified 4-variable
Modified Diet in Renal Disease equation and categorised into four
groups (.60, 45–59 (stage 3a), 30–44 (stage 3b),,30 (stages 4 and
5)). [22] Urine specimens were assayed for total protein, albumin
and creatinine. Urine protein to creatinine ratio (uPCR) and
uACR were calculated as measures of proteinuria. In defining
proteinuria we chose the most conservative reported normal value
for urinary protein excretion of ,150 mg/day. Thus proteinuria
was defined as uPCR$17 mg/mmol (150 mg/g) in at least two of
three samples. [23]
Non-albumin proteinuria was calculated as the difference
between uPCR and uACR. Albuminuria was defined as KDIGO
A2 or A3 (i.e. uACR$3 mg/mmol) in at least two of three
samples. For sensitivity analyses, those with ‘high normal’
albuminuria (uACR 1–3 mg/mmol) in at least two of three
samples were also identified. Isolated NAP was defined as uPCR$
17 mg/mmol in two of three specimens and uACR,3 mg/mmol
in all three specimens. For sensitivity analyses, we also defined
isolated NAP as those with uPCR$17 mg/mmol in two of three
specimens and uACR,1 mg/mmol in order to exclude people
with ‘high normal’ uACR from the NAP definition.
The urine albumin to protein ratio (uAPR) was calculated as the
ratio of average of three uACRs divided by average of three
uPCRs, and uAPR,0.4 was used as a cut off identified as having
high sensitivity and specificity for primary tubulointerstitial
disorders. [16]
BMI was calculated from weight in kilograms divided by height
squared in metres and categorised according to WHO categories
underweight (,18.5 kg/m2), normal (18.5–,25 kg/m2), over-
weight (25-,30 kg/m2), and obese (.=30 kg/m2). [24] Central
obesity was defined as a waist to hip ratio of$0.9 for men or$0.8
for women. [25] Diabetes was defined by having a previous
clinical diagnosis in line with World Health Organization criteria.
[26] Previous cardiovascular event was defined as subject-reported
myocardial infarction, stroke, transient ischemic attack, revascu-
larization, or amputation due to peripheral vascular disease, or
aortic aneurysm. Smoking status was categorized as never smoked,
ex-smoker, and current smoker. Taking a renin-angiotensin
aldosterone system (RAAS) inhibitor was defined by chronic
treatment with any dose of angiotensin converting enzyme
inhibitor or angiotensin receptor blocker.
Blood pressure was measured after a minimum of five minutes
rest in the sitting position, using a validated oscillometric device,
recommended by the British Hypertension Society. The same
device was used for all readings. BP was calculated as the mean of
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three readings that differed by ,10%. Participants were asked
‘Were you told that you may have an issue with your kidneys
before you were contacted to take part in this study?’ Those
answering ‘yes’ were defined as being aware of their CKD
diagnosis.
Statistical analyses
Standard descriptive statistics were used to compare the
characteristics of people with and without albuminuria and
NAP. Univariate and multivariate logistic regression was used to
identify the associations of albuminuria and isolated NAP, and of
both albuminuria and NAP combined (rather than isolated
albuminuria or isolated NAP). Interactions were assessed for age
by gender to test for effect modification in age gender subgroups.
Sensitivity analyses were conducted to assess the associations of
isolated NAP excluding ‘high normal’ uACR. Two methods were
used to compare a single measurement of uACR (from the first
urine specimen) with three measures of uACR from the three
specimens collected in this study. Firstly, the Bland Altman
method was used to examine the degree of agreement between a
single uACR measure and average of three uACR measures,
considering albuminuria as a continuous variable in order to
derive the mean difference (uACR-average uACR), mean absolute
difference (i.e. ignoring the direction of any difference) and 95%
limits of agreement (the values between which 95% of the
differences would be expected to lie). [27] Secondly, considering
albuminuria as a categorical variable, comparing a single uACR
measure with having at least two of three uACR measures $
3 mg/mmol.
All odds ratios are presented with 95% confidence intervals
(CIs) and p values,0.05 are considered statistically significant.
IBM SPSS Statistics for Windows version 19 was used to analyse
the data.
Results
Whole group data
22% (1741) of approximately 8280 eligible participants from 32
GP practices invited to be included in the study agreed to
participate (range 8–34% in different GP practices) and attended
baseline assessment. 1052 (60%) were female, 1168 (67%) were
over 70 years, and mean eGFR was 52.5 mL/min/1.73 m2 (SD
10.4). Median uACR was 0.33 mg/mmol, interquartile range
1.50. Median uPCR was 9.4 mg/mmol, interquartile range
7.63.Characteristics of people in the study are shown in table 1.
Prevalence of proteinuria
Proteinuria of any type (albuminuria (KDIGO A2 or A3) and
isolated NAP) was present in 376 people (22%) (Figure 1). 271
people (16%) had albuminuria based on two of three uACR
positive measures whereas 291 (17%) had abnormal uACR on first
single uACR. Of those with confirmed albuminuria, 78 (4%) had
isolated albuminuria and 193 (11%) had mixed albuminuria and
NAP. 105 people (6%) had isolated NAP (on two of three uPCRs).
539 people (31%) had ‘high normal’ albuminuria (uACR 1–3 mg/
mmol). Defining isolated NAP using a ,1 mg/mmol threshold for
uACR reduced the isolated NAP prevalence to 63 (3.6%). The
distribution of uACR and uPCR for males and females is shown in
Figures 2 and 3 respectively with threshold values. These plots
demonstrate that there are significant numbers of people
(particularly women) with isolated NAP as they fall below the
threshold for albuminuria. There are also some (more noticeable
in men) who have albuminuria but fall below the threshold for
proteinuria.
Albumin to protein ratio
Of those with uPCR$17 mg/mmol (n = 298), 185 (62%) had
uAPR,0.4 suggesting predominantly tubulointerstitial pathology;
45 (24%) were male and 140 (76%) were female.
Associations with proteinuria
Univariate associations with albuminuria were male gender, low
eGFR, diabetes, hypertension, smoking, history of CVD, raised
cholesterol/HDL ratio, lower educational attainment and hsCRP.
In multivariate analysis, the only significant positive associations of
albuminuria were with male gender, lower eGFR, diabetes and
hsCRP (Table 2). There was no association with SES measured by
IMD or education status in the fully adjusted model. Defining
albuminuria by single uACR measure or two of three uACRs did
not alter these associations.
By contrast, isolated NAP was strongly positively associated with
female gender and increasing age, and also associated with
elevated cholesterol/HDL ratio, hsCRP, being aware of CKD
diagnosis and lower SES (defined by education status). The
associations with female gender, age and hsCRP remained in the
multivariable model. No interactions were observed (Table 3).
Sensitivity analyses using isolated NAP defined by a,1 mg/mmol
threshold for uACR (to exclude ‘high normal’ uACR) did not alter
these associations.
Having both albuminuria and NAP (n = 193) was positively
associated with male gender, diabetes, hypertension, smoking,
being aware of CKD diagnosis and hsCRP on univariate analysis.
The associations with male gender, diabetes, smoking, being aware
of CKD diagnosis and hsCRP remained after full adjustment (data
not shown).
One versus multiple measures of proteinuria
Comparing one vs average of three measures of uACR, the
mean difference was 0.0064 mg/mmol (uACR-average
uACR=0.0064, SD 4.69, 95% limits of agreement 29.19 to +
9.20 mg/mmol) (Figure 4). In contrast, the mean absolute
difference (i.e. ignoring the direction of any difference was
0.837 mg/mmol (SD4.62)). In quantifying albuminuria it is the
absolute difference that is most relevant. Comparing single and
multiple uACR measures as categorical variables there was
disagreement between one measure of uACR and three for only
45/1734 (2.6%). Considering the presence albuminuria in at least
2 of 3 specimens as the reference test, the sensitivity of one uACR
was 94.6%, specificity 97.9%, and positive predictive value 89.8%.
Sensitivity of a single PCR (compared to two of three) for isolated
NAP was 81%, specificity was 95%, and positive predictive value
was 48% (prevalence of isolated NAP was only 6%).
Discussion
In this cohort of 1741 people with CKD stage 3, albuminuria
was present in 16% and was associated with NAP in 11%. Isolated
NAP was present in 6%. Presence of albuminuria was associated
with male gender, diabetes, lower eGFR and hsCRP, whereas the
pattern of isolated NAP was different – it was associated with
female gender, increasing age and hsCRP. A single uACR was
sufficient for identification of albuminuria, but due to intra-
individual variation in uACR three measurements are preferable
for quantification of albuminuria.
Albuminuria was relatively uncommon in this cohort suggesting
that most people with CKD stage 3 in primary care have tubulo-
interstitial and/or vascular rather than glomerular pathology. This
low prevalence of albuminuria and the strong association
with adverse renal and cardiovascular outcomes underlies the
Albuminuria and Non-Albumin Proteinuria in CKD
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Table 1. Characteristics of people in the Renal Risk in Derby cohort.
Characteristic Category
Total n=1741 (numbers are n (% of total)
unless otherwise stated)
Gender Male 689 (39.6%)
Female 1052 (60.4%)
Age ,60 128 (7.4%)
60–69 445 (25.6%)
70–79 761 (43.7%)
80+ 407 (23.4%)
Ethnicity White 1698 (97.5%)
Other 43 (2.5%)
Index of multiple deprivation Quintile 1 (most deprived) 151 (8.7%)
Quintile 2 432 (24.8%)
Quintile 3 326 (18.7%)
Quintile 4 447 (25.7%)
Quintile 5 (least deprived) 382 (21.9%)
Education status Group1 (No formal qualifications) 953 (54.7%)
Group 2 (GCSE, Alevel, NVQ1-3) 469 (26.9%)
Group 3 (1st or higher degree, NVQ4–5) 317 (18.2%)
eGFR at study entry Mean (SD) 49.88 (8.08)
.60 418 (24.0%)
45–59 911 (52.3%)
30–44 386 (22.2%)
,30 26 (1.5)
Proteinuria - based on 2 of 3 samples uPCR$17 mg/mmol (150 mg/g) 298 (17.1%)
Albuminuria – based on single sample No albuminuria 1440 (82.7%)
Albuminuria A2 ($3 mg/mmol but ,30 mg/mmol) 247 (14.2%)
Albuminuria A3 ($30 mg/mmol) 44 (2.5%)
Albuminuria - based on 2 of 3 samples No albuminuria 1470 (84.4%)
Albuminuria A2 $3 mg/mmol but ,30 mg/mmol) 231 (13.3%)
Albuminuria A3 ($30 mg/mmol) 40(2.3%)
Non-albumin proteinuria uPCR$17 mg/mmol (in at least 2 of 3 samples) and
uACR,3 mg/mmol (in all samples)
105 (6.0%)
Diabetes Yes 294 (16.9%)
No 1447 (83.1%)
Hypertension On antihypertensive medication 1426 (81.9%)
BP.140/90 at study assessment, but not on
antihypertensive medication
102 (5.9%)
No hypertension 213 (12.2%)
Number of antihypertensive medications None 315 (18.1%)
1 615 (35.3%)
2 488 (28.0%)
3 or more 323 (18.6%)
Taking RAASi Yes 1123 (64.5%)
No 618 (35.5%)
History of CVD Yes 592 (34.0%)
No 1149 (66.0%)
Smoking Current 81 (4.7%)
Ex-smoker 866 (49.7%)
Never 794 (45.6%)
Alcohol No alcohol 711 (40.8%)
Drinking within recommended limits 877 (50.4%)
Drinking above recommended limits 65 (3.7%)
Albuminuria and Non-Albumin Proteinuria in CKD
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importance of detection to identify the minority of people with
CKD who are at increased risk. [5,28,29]
We identified a small number of people with isolated NAP who
would not have been identified by use of uACR alone and
demonstrated clear differences in albuminuria and NAP distribu-
tion patterns in people with CKD 3. We also identified a sub-
group of people with both albumin and non-albumin proteinuria.
A sensitivity analysis showed that NAP was also associated with
‘‘high normal’’ albuminuria in 40% of cases. Nevertheless, these
observations are consistent with albuminuria and NAP reflecting
different renal pathologies (glomerular and tubulo-interstitial). The
associations we observed with albuminuria were similar to those
reported from the CRIC study, except for lack of association with
BMI in our study.[30] The association between albuminuria and
diabetes likely reflects diabetes being a common cause of
glomerulopathy. In retrospective analyses of uACR and uPCR
in people with CKD, Methven et al identified the high sensitivity
of uPCR as a test to identify ‘clinically relevant’ proteinuria
(compared with 24-hour urine collection), and stressed the
equivalence of uACR and uPCR in predicting renal outcomes
and mortality. [15,16] In a separate study they reported increased
risk of death (HR2.34 (95%CI 1.63–3.35)), renal replacement
therapy (HR2.90 (95%CI 1.31–6.43)), and CKD progression (HR
for doubled serum creatinine 2.35 (95% CI 1.62–3.40)) among
Table 1. Cont.
Characteristic Category
Total n=1741 (numbers are n (% of total)
unless otherwise stated)
BMI Normal or underweight 353 (20.3%)
Overweight 738 (42.4%)
Obese 650 (37.3%)
Central obesity Yes 1480 (85.0%)
No 260 (14.9%)
Total cholesterol to HDL ratio .4.5 306 (17.6%)
High sensitivity CRP Median (inter-quartile range) 2.23 (1.14–4.59)
Aware of CKD diagnosis Yes 1026 (58.9%)
No 715 (41.1%)
doi:10.1371/journal.pone.0098261.t001
Figure 1. The distribution of albuminuria (based on 2 of 3 uACRs) and non-albumin proteinuria (based on 2 of 3 uPCRs) in people
with chronic kidney disease stage 3 in the Renal Risk in Derby study.
doi:10.1371/journal.pone.0098261.g001
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people with discordant (i.e. predominantly non-albumin) protein-
uria (low ACR(,30 mg/mmol), high PCR($50 mg/mmol)).[17]
However the magnitude of proteinuria in this study was higher
than our population and different thresholds were used. A study
comparing presence of NAP (identified by a low APR) with
histology from renal biopsy, confirmed the association with
tubulointerstitial pathology. [18] While the prognostic significance
of isolated NAP remains unknown, our findings suggest that
identification of NAP may provide additional diagnostic informa-
tion in certain groups of people, particularly older women. The
low positive predictive value of a single uPCR for isolated NAP in
this study suggests that future prognostic studies would benefit
from using more than one measure. This is important in the light
of the recent suggestion that at least a proportion of NAP may be
artefactual.[31] It is of interest that a marker of inflammation
(hsCRP) was associated with both albuminuria and NAP in this
study. Systemic inflammation is well recognised to be associated
with increased cardiovascular and progression risk in people with
CKD.[32,33] While the association with albuminuria is not
surprising, the association with NAP was unexpected and future
research into the prognostic significance of NAP should also
consider the role of inflammation.
Figure 2. Scatterplot showing the distribution of uACR and uPCR relative to clinically important threshold values for males
(excluding outlier values (ACR over 70 mg/mmol and PCR 150 mg/mmol)). Explanatory footnote for Figure 2: High values have been
excluded (uACR.70 mg/mmol and uPCR.150 mg/mmol) to better illustrate the relationship at lower levels of proteinuria.
doi:10.1371/journal.pone.0098261.g002
Figure 3. Scatterplot showing the distribution of uACR and uPCR relative to clinically important threshold values for females
(excluding outlier values (ACR over 70 mg/mmol and PCR 150 mg/mmol)). Explanatory footnote for Figure 3: High values have been
excluded (uACR.70 mg/mmol and uPCR.150 mg/mmol) to better illustrate the relationship at lower levels of proteinuria.
doi:10.1371/journal.pone.0098261.g003
Albuminuria and Non-Albumin Proteinuria in CKD
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Use of a single urine specimen uACR to define albuminuria
misclassified some individuals in this study compared to using two
of three specimens, but sensitivity, specificity and positive
predictive value of a single uACR were high. Our use of ‘two of
three’ uACRs and uPCRs differs from many studies that have used
a single uACR to identify albuminuria and determine progno-
sis.[5–9] The HUNT 2 study used the mean of three uACR values
to define albuminuria, but did not make comparison with a single
value.[4] Our more restricted definition of albuminuria aimed to
improve specificity and better reflect clinical practice (in which
albuminuria identified in primary care is confirmed by repeat
testing).[11] However, our findings suggest that a single measure of
uACR is sufficient to categorise albuminuria for clinical decision
making. Conversely, we have confirmed substantial intra-individ-
ual variation in uACR values on consecutive days, suggesting that
an average of three uACR measurements is preferable for
quantification of albuminuria. The predictive model developed
by Tangri et al. for progression of CKD to ESRD was based on a
single ACR measure.[2] Our results suggest that further research
on risk prediction models in CKD should also compare the use of
more than one ACR value.
This study had several strengths, including large numbers of
people with CKD, being conducted in a primary care setting,
standardisation of measures, and the use of three morning urine
samples to assess albuminuria and proteinuria. However, it has
several limitations. These analyses were cross sectional, limiting
the ability to infer causality. The majority of patients were already
treated with RAASi at baseline, which may have masked
proteinuria and therefore underestimated true proteinuria prev-
alence. The 2012 KDIGO clinical practice guidelines recom-
mended three categories of albuminuria to grade risk – A1
normal to mildly increased (,3 mg/mmol), A2 moderately
increased (3–30 mg/mmol), and A3 severely increased
(.30 mg/mmol).[14] We chose to examine associations with A2
and A3 combined because the absolute numbers with A3 (ACR.
30 mg/mmol) were small (41 people = 2.4%) and increased risk
has been demonstrated for all grades of albuminuria.[4] Non-
response to recruitment could have caused selection bias, and the
predominantly elderly population could result in survivor bias.
This means that caution should be used applying these results to
other CKD populations. However, our population was similar to
larger studies in the UK primary care setting, suggesting that this
was broadly representative of people with CKD in this
context.[34] Further limitations were that we had no specific
measures of tubular dysfunction or Bence Jones protein to relate to
NAP, and that prevalence of NAP may have been increased by the
high proportion of people taking RAAS inhibitors.
Conclusions
Although albuminuria is relatively uncommon in CKD stage 3
in primary care, its identification is important to determine
prognosis and guide intervention. Albuminuria and isolated NAP
have distinct associations in people with CKD stage 3, likely
reflecting glomerular and tubulo-interstitial pathology respectively.
The prognostic significance of isolated NAP needs further
assessment. A single measure of uACR is sufficient to categorise
albuminuria but three uACR measurements are preferable for
quantification.
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